-
Abanico Coffee Roasters Opens Second San Francisco Location in Inner Sunset
-
San Ġiljan Defeat Paredes 20-12 in Challenger Cup Opener
-
Trump Threatens Heavy Taxes on US Firms Building Data Centers Abroad
-
Kuwait DGCA Delegation Attends ICAO Assembly in Montreal
-
Gozo Minister Clint Camilleri Appointed CPMR Vice-President for Maritime Affairs
-
Charlie Puth and Ellie Goulding to Headline First Johnnie & Co. Festival in Mumbai
-
ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances
-
Maryland Woman Arrested in Decade-Long Cancer Scam Involving Fake Medical Team
-
Panthers Seek NFC South Lead Against Ravens as Baltimore Ends Skid
-
AsiaFIN Holdings Corp. Appoints Fortune Angel INC as U.S. Reseller Partner to Expand Its Agentic and Robotic Process Automation SaaS Business Across New York and the East Coast
-
5 Fun Date Night Ideas That Don't Cost a Fortune
-
Closing a Business with Payroll Taxes Owed - Clear Start Tax Explains the Trust Fund Recovery Penalty
-
Dateline appoints Tony Ferguson as Acting Chairman
-
American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
-
AI Search Engineers Says Longer AI Mode Questions Mean Professional Service Firms Should Answer Full Client Questions Directly on Their Pages
-
Arrive AI's Pro Forma Stockholders' Equity Now Above Nasdaq Minimum Requirement Following Recent Transactions
-
Who Does the Best Rhinoplasty in Sarasota?
-
PodcastOne (NASDAQ:PODC) Launches People Pleasers Podcast hosted by Comedians Leah Rudick and Jessica Michelle Singleton
-
Alset AI Closes Non-Brokered Private Placement Offering
-
Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
-
barq Signs MoU with TenPay Global to Enhance Remittances and Digital Payments in China
-
American Resources Corporation and ReElement Technologies Selected as Part of Winning U.S.-Led Consortium for Kenya's Strategic Mrima Hill Critical Minerals Project
-
Ryde Group Ltd Announces Non-Binding Term Sheet for Proposed Minority Investment in Multi Genius Limited and MOU on Technology Collaboration
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 20
-
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure
-
The DEA Laid The Trap - And State Marijuana Operators Took The Bait
-
Karviva Introduces Unwined Alcohol-Free Malbec and Rose Varieties
-
IDLife Earns Elite 9.04 Brand TrustScore(R) From SuppCo
-
Fortitude Gold Closes $10 Million Private Placement
-
APEX FTE Expo 2026 Unites Aviation Leaders in Singapore and Honors Passenger Experience Excellence
-
APEX Honors Aeroméxico CEO Dr. Andrés Conesa with Historic APEX CEO Lifetime Achievement Award
-
Enmarket to Open Newest Eatery Location in Rincon, GA
-
Eylsia Nicolas Hits No. 1 on Groover's Global and US Singer-Songwriter Charts with "One More Moment," as Taglish Preview of "Wake Me Up for Christmas" Passes One Million Views in Under 24 Hours
-
What Is the Best Social Media Platform for Peptides?
-
WhalesBot Advances Creativity-Driven AI and Coding Education Through Pubbo AI
-
Cytta Air Expands Military Contracting Expertise - Appoints Rear Admiral James "Gib" Godwin III to Advisory Board
-
Tidal Wave Auto Spa Opens New Locations in Murfreesboro, Tennessee and Asheville, North Carolina This Week
-
Peoples Bancorp Announces Cash Dividend
-
Jaguar Health, Inc. Announces Reverse Stock Split
-
Kartoon Studios' Beacon Media Partners With Bandai on Tamagotchi's Landmark 30th Anniversary Times Square Celebration
-
First Phosphate and Zeo Energy Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
-
Taylor Bank Announces $125,000 Commitment to Diakonia's Supportive Living Campus Capital Campaign
-
Ondas, Palantir and Regna AI Host Key Defense Technology Leaders to Accelerate the Path from AI Innovation to Fielded Capability
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, from December 6-9, 2025.
ASH Presentation Details:
Presenting Author: Andrew Kuykendall, MD (Moffitt Cancer Center)
Publication Number: 81
Title: Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study
Oral Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome
Session Date: Saturday, December 6, 2025
Presentation Time: 10:00 AM - 10:15 AM EST
Location: Orlando Convention Center, W414CD
Presenting Author: Aniket Bankar, MD (Princess Margaret Cancer Centre)
Publication Number: 5588
Title: Comprehensive Analyses of Patient-Reported Outcomes from the Phase 3 VERIFY Study of Rusfertide or Placebo Plus Current Standard of Care for Polycythemia Vera
Poster Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 8, 2025
Presentation Time: 6:00 PM - 8:00 PM EST
Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)
Presenting Author: Joseph Shatzel, MD (Oregon Health & Science University)
Publication Number: 5587
Title: Should Dermatologic Examinations Become Routine Standard of Care in Patients with Polycythemia Vera, Observations from the Phase 3 VERIFY Study Prior to Rusfertide Exposure
Poster Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 8, 2025
Presentation Time: 6:00 PM - 8:00 PM EST
Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)
Presenting Author: Naveen Pemmajaru, MD (MD Anderson Cancer Center)
Publication Number: 3810
Title: Long-term Rusfertide Treatment in Polycythemia Vera: Initial Results from the Phase 2
THRIVE Extension Study
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Session Date: Sunday, December 7, 2025
Presentation Time: 6:00 PM - 8:00 PM EST
Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and in the NDA submission for rusfertide expected by end of 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company, Inc. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
[email protected]
+1 833 500 0061
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
M.King--AT